The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Acquired resistance to PD-1 blockade in NSCLC.
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Danish Memon
No Relationships to Disclose
 
Jia Luo
No Relationships to Disclose
 
Isabel Ruth Preeshagul
Consulting or Advisory Role - AstraZeneca; Pfizer
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Chad Vanderbilt
Consulting or Advisory Role - DocDoc; Paige.AI
 
Martin L. Miller
No Relationships to Disclose
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb